Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
[Case Report] Issue 337: A Case of Nilotinib Treatment in a Patient with High-Risk Locally Advanced Nasopharyngeal Cancer
View details
→
[Voice from a Doctor] Exploring personalized treatment options for pancreatic cancer, bringing new hope to patients with advanced stages
[Case Study] Issue 336: Nilotinib Treatment for Advanced Tongue Cancer
November 2024
[Shengxin Case] Issue 335: A Case Report on Nilotinib Treatment for Pancreatic Cancer
Good news! Nivolumab's indication for head and neck tumors has been added to the National Medical Insurance Catalog.